Protalix BioTherapeutics, Inc. (PLX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q3 '24: 18M Q4 '24: 18.2M Q1 '25: 10.1M Q2 '25: 15.7M Q3 '25: 17.9M Q4 '25: 9.1M Q1 '26: 33.8M Q2 '26: 19.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q4 '16: 129K Q1 '17: 801K Q2 '17: 835K Q3 '17: 1.5M Q4 '17: 915K Q1 '18: 1.6M Q2 '18: -177K Q3 '18: -1.3M Q4 '16 Q1 '17 Q2 '17 Q3 '17 Q4 '17 Q1 '18 Q2 '18 Q3 '18

Operating Income Quarterly

-8M 0 8M 16M 24M Q3 '24: 4M Q4 '24: 7.2M Q1 '25: -4.1M Q2 '25: 1.2M Q3 '25: 2.1M Q4 '25: -4.7M Q1 '26: 21.1M Q2 '26: 4.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-7M 0 7M 14M 21M Q3 '24: 3.2M Q4 '24: 6.5M Q1 '25: -3.6M Q2 '25: 164K Q3 '25: 2.4M Q4 '25: -5.5M Q1 '26: 18.3M Q2 '26: 3.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 3M 6M 9M Q3 '24: 8.4M Q4 '24: 3.9M Q1 '25: 8.2M Q2 '25: 5.9M Q3 '25: 8.3M Q4 '25: 4.6M Q1 '26: 4.1M Q2 '26: 7.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-16M -8M 0 8M 16M 24M Q3 '24: 4.1M Q4 '24: 4M Q1 '25: -5.1M Q2 '25: -5.2M Q3 '25: -3.7M Q4 '25: 2M Q1 '26: 22M Q2 '26: -10.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-16M -8M 0 8M 16M 24M Q3 '24: 4M Q4 '24: 3.6M Q1 '25: -5.4M Q2 '25: -5.7M Q3 '25: -4.2M Q4 '25: 1.6M Q1 '26: 21.3M Q2 '26: -11M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q1 '24: 73M Q2 '24: 73.3M Q3 '24: 81.2M Q1 '25: 76.6M Q2 '25: 81.3M Q3 '25: 80.8M Q1 '26: 83M Q2 '26: 82.6M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.16 -0.08 0.00 0.08 0.16 0.24 Q3 '24: -0.09 Q4 '24: 0.04 Q1 '25: 0.05 Q2 '25: 0.08 Q3 '25: 0.08 Q4 '25: -0.09 Q1 '26: 0.18 Q2 '26: 0.23 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.